Ensuring Transparency and Consistency in the Value Assessment of Cancer Therapies [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Iskrov, Stefanov Tags: CORRESPONDENCE Source Type: research
Comment on the American Society of Clinical Oncology Value Statement [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Weber, Drakeman Tags: CORRESPONDENCE Source Type: research
International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Malone, Berg, Claxton, Garrison, IJzerman, Marsh, Neumann, Sculpher, Towse, Uyl-de Groot, Weinstein Tags: CORRESPONDENCE Source Type: research
Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Angelis, Kanavos Tags: CORRESPONDENCE Source Type: research
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received [ASCO SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Schnipper, Davidson, Wollins, Blayney, Dicker, Ganz, Hoverman, Langdon, Lyman, Meropol, Mulvey, Newcomer, Peppercorn, Polite, Raghavan, Rossi, Saltz, Schrag, Smith, Yu, Hudis, Vose, Schilsky Tags: Quality of Care, Cost of Cancer Care ASCO SPECIAL ARTICLE Source Type: research
Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up [Cancer Prevention and Control]
Conclusion
Although telephone counseling led to lower testing uptake, our findings suggest that telephone counseling can be effectively used to increase reach and access without long-term adverse psychosocial consequences. Further work is needed to determine long-term adherence to risk management guidelines and effective strategies to boost utilization of primary and secondary preventive strategies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Kinney, Steffen, Brumbach, Kohlmann, Du, Lee, Gammon, Butler, Buys, Stroup, Campo, Flores, Mandelblatt, Schwartz Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Outcomes Research, Quality of Life Cancer Prevention and Control Source Type: research
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study [Gastrointestinal Cancer]
Conclusion
To our knowledge, this study provides the first validation of the 12-gene Recurrence Score assay in stage III colon cancer without chemotherapy and showed the heterogeneity of recurrence risks in stage III as well as in stage II colon cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Yamanaka, Oki, Yamazaki, Yamaguchi, Muro, Uetake, Sato, Nishina, Ikeda, Kato, Kanazawa, Kusumoto, Chao, Lopatin, Krishnakumar, Bailey, Akagi, Ochiai, Ohtsu, Ohashi, Yoshino Tags: Gastrointestinal Cancer Source Type: research
Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival [Gastrointestinal Cancer]
Conclusion
We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Yuan, Qian, Babic, Morales-Oyarvide, Rubinson, Kraft, Ng, Bao, Giovannucci, Ogino, Stampfer, Gaziano, Sesso, Buring, Cochrane, Chlebowski, Snetselaar, Manson, Fuchs, Wolpin Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Gastrointestinal Cancer Source Type: research
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium [Epidemiology]
Conclusion
The heterogeneous associations of risk factors with ovarian cancer subtypes emphasize the importance of conducting etiologic studies by ovarian cancer subtypes. Most established risk factors were more strongly associated with nonserous carcinomas, which demonstrate challenges for risk prediction of serous cancers, the most fatal subtype. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Wentzensen, Poole, Trabert, White, Arslan, Patel, Setiawan, Visvanathan, Weiderpass, Adami, Black, Bernstein, Brinton, Buring, Butler, Chamosa, Clendenen, Dossus, Fortner, Gapstur, Gaudet, Gram, Hartge, Hoffman-Bolton, Idahl, Jones, Kaaks, Kirsh, Koh, Lac Tags: Cancer Etiology, Behavioral and Lifestyle Risk Factors, Epidemiology Source Type: research
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial [Gynecologic Cancer]
Conclusion
No significant survival benefit was found for CPT-P. Both regimens were well tolerated, but the toxicity profiles differed significantly. Treatment with existing anticancer agents has limitations to improving the prognosis of CCC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Sugiyama, Okamoto, Enomoto, Hamano, Aotani, Terao, Suzuki, Mikami, Yaegashi, Kato, Yoshikawa, Yokoyama, Tanabe, Nishino, Nomura, Kim, Kim, Pignata, Alexandre, Green, Isonishi, Terauchi, Fujiwara, Aoki Tags: Chemotherapy Gynecologic Cancer Source Type: research
The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions [Clinical Practice]
Conclusion
Oncologist implicit racial bias is negatively associated with oncologist communication, patients’ reactions to racially discordant oncology interactions, and patient perceptions of recommended treatments. These perceptions could subsequently directly affect patient-treatment decisions. Thus, implicit racial bias is a likely source of racial treatment disparities and must be addressed in oncology training and practice. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Penner, Dovidio, Gonzalez, Albrecht, Chapman, Foster, Harper, Hagiwara, Hamel, Shields, Gadgeel, Simon, Griggs, Eggly Tags: Quality of Care Clinical Practice Source Type: research
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [Thoracic Oncology]
Conclusion
Consistent with its activity in ASCEND-1, ceritinib treatment provided clinically meaningful and durable responses with manageable tolerability in chemotherapy- and crizotinib-pretreated patients, including those with brain metastases. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Crino, Ahn, De Marinis, Groen, Wakelee, Hida, Mok, Spigel, Felip, Nishio, Scagliotti, Branle, Emeremni, Quadrigli, Zhang, Shaw Tags: Chemotherapy Thoracic Oncology Source Type: research
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 [Thoracic Oncology]
Conclusion
Compared with chemotherapy, crizotinib demonstrated a significantly higher IC-DCR in patients with tBM. Improvements in IC-TTP were not statistically significant in patients with or without tBM, although sensitivity to detect treatment differences in or between the two subgroups was low. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Solomon, Cappuzzo, Felip, Blackhall, Costa, Kim, Nakagawa, Wu, Mekhail, Paolini, Tursi, Usari, Wilner, Selaru, Mok Tags: Chemotherapy Thoracic Oncology Source Type: research
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [Hematologic Malignancy]
Conclusion
Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today. This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of patients with CML will have a great effect on future health care costs as long as continuous TKI treatment is required. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Bower, Bjorkholm, Dickman, Hoglund, Lambert, Andersson Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Hematologic Malignancy Source Type: research
Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation [Hematologic Malignancy]
Conclusion
Our findings suggest that the repeated infusion of MSCs might inhibit cGVHD symptoms in patients after HLA-haplo HSCT, accompanied by changes in the numbers and subtypes of T, B, and NK cells, leading to the acquisition of immune tolerance. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Gao, Zhang, Hu, Liu, Kong, Lou, Su, Yang, Li, Liu, Zhang, Gao, Zhu, Wen, Wang, Chen, Zhong, Zhang Tags: Leukemia, Combined Therapy, Biological Therapy Hematologic Malignancy Source Type: research
